ETAP-Lab provides preclinical models and pharmacology services in the fields of Dermatology and Neurology. ETAP-Lab works for about 150 clients worldwide and performed more than 800 studies.

The company has strong expertise in the field of Dermatology research to evaluate both drugs, regenerative approach (e.g. skin grafting) and medical devices. We offer a large portfolio in vivo rodent models such as chronic skin inflammation, ischemic ulceration, psoriasis, hyperkeratosis, wound healing, atopic dermatitis, actinic keratosis, skin cancer…

ETAP-Lab is also leader in the field of preclinical stroke research with a unique portfolio consisting of innovative and translational models proposed under the brand STROK@LLIANCE. We also provide non GLP safety studies related to stroke (Hemorrhagic transformations, drug-drug interaction with the standard of care). It is the only CRO 100% dedicated to preclinical stroke research. The Strok@lliance Scientific Advisory Board is coordinated by a renowned scientist in the field of Stroke : Pr Denis Vivien (PhIND Laboratory, INSERM/Caen university).

Also, ETAP-Lab provide both in vitro and in vivo services in the fields of Neurodegenerative diseases, namely Alzheimer’s and Parkinson’s diseases, based on its unique know-how in production of stable and soluble toxic oligomers (Amyloid-Beta 1-42 oligomers, Tau oligomers, Alpha-synuclein oligomers).

With a largel panel of tools and methodologies, ETAP-Lab is also able to address most of routine protocols in rodents (stereotaxic injection, medical imagery, microsurgery).

With more than 2 decades of experience, ETAP-Lab has become a best-in-class service provider for top tier Pharma, Medical device and Agri-food companies and obtained ISO9001:v2015 certification for all its preclinical services.

ETAP-Lab provided customized solution for drug testing. Thus, our team is able to develop and customize relevant animal models with high translational value that fit to specific goals, from the proof-of-concept to the early development.